Converseer
No Result
View All Result
  • Home
  • Politics
  • Jobs
  • Metro
  • Sports
  • Tech
  • Health
  • News
    • Business
    • Education
    • Entertainment
    • Lifestyle
    • Science & Nature
    • Tourism
  • Trends
PRICING
SUBSCRIBE
  • Home
  • Politics
  • Jobs
  • Metro
  • Sports
  • Tech
  • Health
  • News
    • Business
    • Education
    • Entertainment
    • Lifestyle
    • Science & Nature
    • Tourism
  • Trends
No Result
View All Result
Converseer
No Result
View All Result
  • Home
  • Politics
  • Jobs
  • Metro
  • Sports
  • Tech
  • Health
  • News
  • Trends

Pharma Stock Skyrockets Over 100%

August 19, 2026
in News
Reading Time: 2 mins read

Daily Caller News Foundation

Shares of Moderna more than doubled Wednesday after the company and Merck announced positive results from a late-stage trial of an experimental cancer vaccine, though the companies have yet to release detailed data from the results.

The Phase 3 trial met its primary endpoint, according to the drugmakers, with the vaccine combination significantly improving the amount of time patients remained free of melanoma compared with Keytruda alone. But Moderna and Merck have not yet disclosed the specific effect size, survival times or full statistical results for the trial, leaving investors and outside researchers waiting for a clearer picture of how substantial the benefit actually was.

The trial tested Moderna’s mRNA-based vaccine alongside Merck’s Keytruda immunotherapy in 1,137 patients with higher-risk melanoma whose tumors had been surgically removed, as reported by CNBC. The combination also reduced the risk of melanoma spreading to distant parts of the body, according to the companies.

Moderna shares jumped more than 130% in morning trading, while Merck rose more than 10%. The dramatic difference reflects the companies’ relative sizes, with Merck valued at roughly $333 billion before the surge compared with about $25 billion for Moderna.

The companies said the results build on earlier Phase 2 findings and could eventually lead to the personalized vaccine becoming a new treatment option for melanoma. However, the Phase 3 study is still being evaluated for overall survival, and the drugmakers plan to release additional results at an upcoming medical meeting.

The vaccine was designed differently from conventional cancer treatments. Researchers identified mutations specific to an individual patient’s tumor and used Moderna’s mRNA technology to train the immune system to recognize those mutations. The vaccine was then administered alongside Keytruda, which helped the immune system attack cancer cells.

Earlier Phase 2 results showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death, but the Phase 3 results didn’t provide comparably detailed figures.

Moderna received criticism during the Covid-era for reportedly tracking online content that was critical of covid vaccines.

Merck and Moderna were also testing the personalized vaccine against other cancers, including lung, bladder and kidney cancer. Whether the approach can produce similarly strong results across those diseases remains an open question.

The companies didn’t announced when they would seek U.S. approval, though Merck executives said they expected to begin discussions with regulators about the treatment and its safety in the coming months.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact licensing@dailycallernewsfoundation.org.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact licensing@dailycallernewsfoundation.org.

(DCNF)

Tags: United States

RelatedNews

News

DSS Officer Admits Collecting N2.5million From Applicants In Failed Recruitment Process, Victims Demand Refund

November 10, 2026
Police arrest Navy personnel for allegedly assaulting officers
News

Police in Katsina bursts suspected fraud syndicate with multiple BVNs, NINs

November 10, 2026
News

World Bank Commits $200m To Boost Nigeria’s Fish Production

November 10, 2026
News

EXCLUSIVE: Trump DOJ Slaps California City With Lawsuit Over Sky-High Gun-Carry Permit Fees

November 10, 2026
News

The Federal Government, has suspended all reviews of broadcast licence fees until further notice.

November 10, 2026
News

2027: Makinde Accuses APC Of Stealing APM’s ‘Reset Agenda’

November 9, 2026
Next Post

Uganda: Accounting Officers Must Honour Committee Summons – Speaker

36 Aid Workers Killed In South Sudan As Attacks Surge

Latest News

LIVE STREAM: Paris FC vs HB Koege | Women’s Champions League

LIVE STREAM: Paris FC vs HB Koege | Women’s Champions League

November 19, 2026
C’River’s Project Grow concludes training for 1,800 farmers across 18 LGAs, reinforces market access opportunities

C’River’s Project Grow concludes training for 1,800 farmers across 18 LGAs, reinforces market access opportunities

November 19, 2026
LIVE STREAM: Egypt U17 vs Greece U17 | U17 FIFA World Cup

LIVE STREAM: Egypt U17 vs Greece U17 | U17 FIFA World Cup

November 19, 2026
LIVE STREAM: Argentina U17 vs Australia U17 | U17 FIFA World Cup

LIVE STREAM: Argentina U17 vs Australia U17 | U17 FIFA World Cup

November 19, 2026
LIVE STREAM: Qatar U17 vs Panama U17 | U17 FIFA World Cup

LIVE STREAM: Qatar U17 vs Panama U17 | U17 FIFA World Cup

November 19, 2026

Topics

  • Latest News
  • Nigeria
  • Africa
  • Europe
  • Asia
  • Americas
  • United States

Social Media

  • WhatsApp
  • Facebook
  • X (Twitter)
  • YouTube
  • LinkedIn

Special Topics

  • Column
  • Bassey Otu
  • Bola Tinubu
  • Special Reports
  • Profile & Biography
  • Opinion
  • Latest News
  • About
  • Advertise
  • Contact
  • Daily Newsletter
  • Privacy Policy
  • Terms Of Use
  • Write For Us

© 2026 Converseer.

No Result
View All Result
  • About
  • Advertise
  • Contact
  • Daily Newsletter
  • Privacy Policy
  • Terms Of Use
  • Write For Us

© 2026 Converseer.